In vitro susceptibility to 19 agents other than &bgr;-lactams among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission

Objectives As part of the multicentre Antibiotic Therapy Optimisation Study, MIC values of 19 non-β-lactam agents were determined for third-generation cephalosporin-resistant Escherichia coli , Klebsiella species and Enterobacter species (3GCREB) isolates collected in German hospitals. Methods A total of 328 E. coli , 35 Klebsiella spp. (1 Klebsiella oxytoca and 34 Klebsiella pneumoniae ) and 16 Enterobacter spp. (1 Enterobacter aerogenes and 15 Enterobacter cloacae ) isolates were submitted to broth microdilution antimicrobial susceptibility testing with the MICRONAUT system. MICs of fluoroquinolones (levofloxacin and moxifloxacin), aminoglycosides (gentamicin, tobramycin, amikacin, streptomycin, neomycin and paromomycin), tetracyclines (tetracycline, minocycline and tigecycline), macrolides (erythromycin, clarithromycin and azithromycin) and miscellaneous agents [trimethoprim/sulfamethoxazole, chloramphenicol, nitrofurantoin, colistin and fosfomycin intravenous (iv)] were determined and reviewed against 2016 EUCAST breakpoints. Results The MIC of levofloxacin was >2 mg/L for 128 of 328 E. coli and 8 of 35 Klebsiella spp., but only 1 of 16 Enterobacter spp. Rates of resistance to trimethoprim/sulfamethoxazole were high (>70%), except for Enterobacter spp. Rates of resistance to colistin and fosfomycin iv were still low. About 20% of the tested isolates were resistant to chloramphenicol. Only 1 (of 328) E. coli isolate had an MIC of amikacin >16 mg/L and only 33 of 328 E. coli and 1 of 35 Klebsiella spp. had an MIC of tobramycin >4 mg/L, whereas average gentamicin MICs were in general more elevated. A tigecycline MIC >2 mg/L was only found for 1 of 16 Enterobacter spp., but in none of the E. coli or Klebsiella spp. isolates. Conclusions Our study gives insight into previously unreported non-β-lactam MIC distributions of 3GCREB isolates.

[1]  A. Tsakris,et al.  Comparative evaluation of minocycline susceptibility testing methods in carbapenem-resistant Acinetobacter baumannii. , 2016, International journal of antimicrobial agents.

[2]  P. Nordmann,et al.  Features of the mcr-1 Cassette Related to Colistin Resistance , 2016, Antimicrobial Agents and Chemotherapy.

[3]  I. Bekeredjian-Ding,et al.  False non-susceptible results of tigecycline susceptibility testing against Enterobacteriaceae by an automated system: a multicentre study. , 2016, Journal of medical microbiology.

[4]  J. Knobloch,et al.  Colonization with third-generation cephalosporin-resistant Enterobacteriaceae on hospital admission: prevalence and risk factors. , 2016, The Journal of antimicrobial chemotherapy.

[5]  Nikolaos A. Triarides,et al.  Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. , 2016, International journal of antimicrobial agents.

[6]  S. Harbarth,et al.  Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. , 2015, The Journal of antimicrobial chemotherapy.

[7]  K. Peck,et al.  In Vitro Activities of 21 Antimicrobial Agents Alone and in Combination with Aminoglycosides or Fluoroquinolones against Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates Causing Bacteremia , 2015, Antimicrobial Agents and Chemotherapy.

[8]  N. Woodford,et al.  Comparative in vitro activity of sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim and other agents against multiresistant Gram-negative bacteria. , 2014, The Journal of antimicrobial chemotherapy.

[9]  N. Woodford,et al.  Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change? , 2013, The Journal of antimicrobial chemotherapy.

[10]  J. Schrenzel,et al.  Decolonization of intestinal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae with oral colistin and neomycin: a randomized, double-blind, placebo-controlled trial. , 2013, The Journal of antimicrobial chemotherapy.

[11]  Timothy R. Walsh,et al.  Tackling antibiotic resistance , 2011, Nature Reviews Microbiology.

[12]  Neil Woodford,et al.  What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. , 2011, International journal of antimicrobial agents.

[13]  A. Widmer,et al.  Effectiveness of a new decolonisation regimen for eradication of extended-spectrum β-lactamase-producing Enterobacteriaceae. , 2011, The Journal of hospital infection.

[14]  N. Wellinghausen,et al.  Evaluation of the Merlin MICRONAUT System for Rapid Direct Susceptibility Testing of Gram-Positive Cocci and Gram-Negative Bacilli from Positive Blood Cultures , 2007, Journal of Clinical Microbiology.

[15]  H. Seifert,et al.  Comparative in vitro activity of oral antimicrobial agents against Enterobacteriaceae from patients with community-acquired urinary tract infections in three European countries. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  A. Oliver,et al.  Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  T. Pruett Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America , 2010 .